RELAX-AHF and PROTECT studies find targeting WHF may reduce readmissions and save lives

(Press-News.org) Athens, 17 May 2014: Worsening symptoms and signs of heart failure (WHF) in patients admitted to a hospital is a common sign of treatment failure and can lead to long-term consequences for the patient, including longer length of hospitalization and a higher risk for readmission and death, according to a late-breaking study (RELAX-AHF, PROTECT) presented in Athens at the ESC's Heart Failure Congress 2014

Heart failure is the most common reason for admission to hospital in people over 65 years old and affects millions of people each year. Research has shown that the outcomes of patients admitted with Acute Heart Failure (AHF) are dire with significant time spent in the hospital and high rates of readmissions or death within 6 months. Currently available therapies such as i.v. diuretics and vasodilators, may relieve some of the symptoms of AHF including dyspnoea, but most probably do not affect short term outcomes.

"Worsening heart failure is a clinical event occurring during an admission for acute heart failure defined as worsening of the symptoms and signs that brought the patient to the hospital requiring additional intravenous or mechanical therapy," said Beth Davison, lead author on the RELAX-AHF study and vice president of Momentum Research Inc. "It prolongs the hospital stay and is associated with increased risk for heart failure readmission within 2 months and death within 6 months. Preventing this early event would not only reduce the patient's suffering during the admission but possibly also reduce its longer-term consequences."

In data pooled from the PROTECT Pilot, PROTECT, Pre-RELAX-AHF, and RELAX-AHF studies the association of WHF with length of stay, mortality and HF re-hospitalization were examined. In 3691 patients, death or WHF occurred in 12.4%. WHF was associated with a mean increase in the length of hospital stay of 5.2 days (95% confidence intervals [CI] 4.6-5.8 days); a hazard ratio (HR) for 60-day HF readmission or CV death of 1.64 (CI 1.34-2.01) and a HR for 180-day mortality of 1.93 (1.55-2.41) – all P< 0.001. WHF was also associated with larger increases in markers of renal and hepatic dysfunction during the first days of admission.

The association of WHF with these outcomes remained robust after adjustment for changes in these markers at day 2 on top of adjustment for baseline characteristics. The association of WHF with mortality was significant regardless of what therapy was given for WHF, although patients who needed IV inotropes or mechanical support had higher mortality.

"Because WHF is associated with more adverse outcome physicians should monitor closely patients who develop WHF during admission," said Dr. Davison. "As suggested by the results of the RELAX-AHF study, future therapy may reduce the occurrence of WHF and some of its downstream effects."

INFORMATION:

About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About the Heart Failure Association (HFA) The Heart Failure Association (HFA) is a registered branch of the ESC. Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

For practical information about heart failure aimed at patients, families and caregivers, visit the HFA's Heart Failure Matters website. (Website)

Did you want to tweet about our congress? - if you do, please use the official #heartfailure2014 hashtag! Thank you.

Information for journalists attending Heart Failure 2014

• If you have any question or request regarding interview opportunities, please contact: ESC Press Office
Jacqueline Partarrieu
press@escardio.org
Tel: +33 6 22 83 45 76 (off site support number)

Heart Failure 2014 takes place in Athens, Greece, on 17-20 May 2014 at the MAICC Congress Center.

Look here for the current final programme: http://www.escardio.org/congresses/heart-failure-2014/Documents/fp-hf2014-web.pdf?hit=highlight-on

For full details of a session, have a look at the Scientific Programme & Planner: http://spo.escardio.org/default.aspx?eevtid=68&showResults=False

On-site Press registration process: Free registration applies to press representatives upon receipt of valid credentials and a fully completed embargo form.
Credential: either your ID press card or letter of assignment with proof of 3 published articles
Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives
The decision of the ESC Press Office is final regarding all press registration requests.
When your registration as press will be validated you will be given a press badge and the press kit.
The press working area is located in front of the registration desks. It features free wifi and a printer linked to a computer.